Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Filtrer les résultats de recherche
Sélectionner modèles de données

Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

22 Résultats de recherche.

Colorectal Cancer NCT00217737 - Leucovorin Supplemental Form Colon Cancer E5202 NCT00217737

- 23/03/2015 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue

Groupes Item: Header, Therapy

E5202 Leucovorin Supplemental Form Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer NCT00217737 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=604FA9F1-CB9F-41AD-E040-BB89AD433F0D

Breast Cancer combination chemotherapies (NCT00024102) - CYCLOPHOSPHAMIDE MEDICATION CALENDAR (CALGB 49907, NCT00024102)

- 18/03/2015 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue

Groupes Item: Header, Medication calendar

Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer NCT00024102 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A50CFEAE-D13B-3952-E034-080020C9C0E0

Breast Cancer DRUG SUPPLY NCT00024102 CALGB 49907 - CAPECITABINE DRUG SUPPLY RECORD FORM NCT00024102

- 20/05/2015 - 1 Formulaire, 2 Groupes Item, 22 Eléments de données, 1 Langue

Groupes Item: Header, Drug Supply

CALGB: 49907 CAPECITABINE DRUG SUPPLY RECORD FORM Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer NCT00024102 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A50CE624-6F5F-37E3-E034-080020C9C0E0

Treatment Chemotherapy-docetaxel/capecitabine arm Breast Cancer NCT00433589

- 29/07/2015 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue

Groupes Item: Header, Chemotherapy Anthracycline Arm

Treatment Chemotherapy-docetaxel/capecitabine arm Breast Cancer NCT00433589 Breast Cancer NCT00433589 Treatment - Chemotherapy-docetaxel/capecitabine arm - 2499349v1.0 Chemotherapy-docetaxel/capecitabine arm Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes NCT00433589 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=196E5474-4AF3-680E-E044-0003BA3F9857

Cycle Dose Drug Form (D2R) Endometrial Cancer (NCT00942357)

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 38 Eléments de données, 1 Langue

Groupes Item: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values

GOG-0258 Cycle Dose Drug Form (D2R) Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer NCT00942357 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=644E6D14-3E4C-95F3-E040-BB89AD4357FF

Cycle Dose Drug Form Fallopian Tube Cancer (NCT00262847)

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 38 Eléments de données, 1 Langue

Groupes Item: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values

GOG-0218 Cycle Dose Drug Form Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer NCT00262847 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F11B7C47-A6FE-54E9-E034-0003BA3F9857

Cycle Dose Drug Form (D2R) Ovarian Cancer (NCT00954174)

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 38 Eléments de données, 1 Langue

Groupes Item: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values

GOG-0261: Cycle Dose Drug Form (D2R) Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer NCT00954174 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=64F29740-0457-692F-E040-BB89AD432164

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00108745)

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 41 Eléments de données, 1 Langue

Groupes Item: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values

Cycle Dose Drug Form, GOG-0212, Form D2R Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer NCT00108745 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E74972BD-ECF1-48B2-E034-0003BA3F9857

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00565851)

- 09/01/2015 - 1 Formulaire, 2 Groupes Item, 35 Eléments de données, 1 Langue

Groupes Item: Header, TREATMENT CYCLE AND MODIFICATION

GYNECOLOGIC ONCOLOGY GROUP Cycle Dose Drug Form - FORM D2R Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer NCT00565851 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA671E4E-F217-4DDB-E034-0003BA12F5E7

Cycle Dose Drug Form D2R Fallopian Tube Cancer (NCT00951496)

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 41 Eléments de données, 1 Langue

Groupes Item: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values

Gynecologic Oncology Group Cycle Dose Drug Form (Form D2R) Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00951496 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4F53E994-CCD2-730F-E044-0003BA3F9857

AMC-063 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F37)

- 09/10/2017 - 1 Formulaire, 4 Groupes Item, 14 Eléments de données, 1 Langue

Groupes Item: Header - AIDS and Cancer Specimen Resource (ACSR) Procurement Form, Specimen Procurement, Contact Information, Comments

AMC-063 AIDS and Cancer Specimen Resource (ACSR) Procurement Form (F63) Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=815F9798-9F3D-E20D-E040-BB89AD435094

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Screening - Subject Identification; Demography; Disease Characteristics; Status at Screening; Anti-Cancer Therapy; Anti-Cancer Radiotherapy; Medical Conditions

- 15/03/2021 - 1 Formulaire, 12 Groupes Item, 64 Eléments de données, 1 Langue

Groupes Item: Inform Screening, Subject number, Date of Visit/ Assessment, Local Laboratories, Subject identification, Demography, Disease Characteristics, Metastatic Disease, Status at Screening, Anti-Cancer Therapy, Anti-Cancer Therapy , Medical Conditions

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.